Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adcetris in active diffuse cutaneous systemic sclerosis
NCT03198689Phase 2Completed
- Start
- May 2019
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in diffuse cutaneous systemic sclerosis (dcSSc). Started May 2019; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT03198689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198689.